Pure MHC, LLC

Pure MHC, LLC is a biotechnology startup with a mission to create a novel class of therapeutics for the treatment of cancer and infectious diseases. The company specializes in disease-specific target identification and validation for use in immunotherapeutic drug development. Its proprietary technology provides access to every protein synthesized or degraded inside a cell, identifying previously unknown disease targets. Pure MHC's key enabling technology, Soluble HLA (sHLA), allows for the expression of a pure source of HLA in a diseased cell of choice. Using mass spectroscopy techniques, Pure MHC compares peptides recovered from HLA complexes extracted from cancer, infected, and normal cells, identifying unique peptides representing novel disease targets. The company has also developed a unique class of monoclonal antibodies specific for the biomarkers it discovers and validates, known as T Cell Receptor mimics (TCRm). Pure MHC's approach shows promise for disease treatment, diagnostics, and pre-clinical development assays in the biotechnology industry.